Drug Trial Radar · NCT05064059
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
Last checked: Nov 19, 2026Latest source record: May 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
441
Actual
Start
Nov 10, 2021
Primary completion
Aug 15, 2024
Study completion Feb 21, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in participants with metastatic colorectal cancer. The study will also compare MK-4280A with the standard of care treatment of regorafenib and TAS-102 (trifluridine and tipiracil). The primary study hypothesis is that coformulated favezelimab/pembrolizumab (MK-4280A) is superior to standard of care with respect to overall survival.
Conditions
- Colorectal Cancer
Interventions
favezelimab/pembrolizumabBiological
Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion
regorafenibDrug
Oral
TAS-102Drug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to approximately 33 months
Locations
152 sites in 21 countries. Site status is shown where the registry gives one.
Georgetown University Hospital ( Site 1148)
Washington D.C., District of Columbia
Sibley Memorial Hospital ( Site 1143)
Washington D.C., District of Columbia
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 1118)
Marietta, Georgia
Norton Cancer Institute ( Site 1139)
Louisville, Kentucky
Rutgers Cancer Institute of New Jersey ( Site 1105)
New Brunswick, New Jersey
Memorial Sloan Kettering Cancer Center ( Site 1703)
New York, New York
Oregon Health & Science University ( Site 1141)
Portland, Oregon
MUSC Hollings Cancer Center ( Site 1715)
Charleston, South Carolina
The West Clinic, PLLC dba West Cancer Center ( Site 1149)
Germantown, Tennessee
UT Southwestern Medical Center ( Site 1709)
Dallas, Texas
Intermountain Medical Center ( Site 1707)
Murray, Utah
Inova Schar Cancer Institute ( Site 1130)
Fairfax, Virginia
VCU Health Adult Outpatient Pavillion ( Site 1712)
Richmond, Virginia
Blue Ridge Cancer Care ( Site 1718)
Roanoke, Virginia
Seattle Cancer Care Alliance ( Site 1107)
Seattle, Washington
Westmead Hospital ( Site 0057)
Westmead, New South Wales, Australia
Royal Brisbane and Women s Hospital ( Site 0058)
Herston, Queensland, Australia
Queen Elizabeth Hospital ( Site 0050)
Woodville South, South Australia, Australia
Frankston Hospital ( Site 0056)
Frankston, Victoria, Australia
Western Health-Sunshine & Footscray Hospitals ( Site 0052)
St Albans, Victoria, Australia
St John of God Subiaco Hospital ( Site 0051)
Perth, Western Australia, Australia
London Regional Cancer Program - London HSC ( Site 0154)
London, Ontario, Canada
The Ottawa Hospital ( Site 0151)
Ottawa, Ontario, Canada
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0155)
Toronto, Ontario, Canada
Centro Investigacion Cancer James Lind ( Site 0204)
Temuco, Araucania, Chile
IC La Serena Research ( Site 0202)
La Serena, Coquimbo Region, Chile
Clinica Puerto Montt ( Site 0211)
Port Montt, Los Lagos Region, Chile
Fundacion Arturo Lopez Perez FALP ( Site 0208)
Santiago, Region M. de Santiago, Chile
Oncovida ( Site 0209)
Santiago, Region M. de Santiago, Chile
Clínica Vespucio ( Site 0205)
Santiago, Region M. de Santiago, Chile
Pontificia Universidad Catolica de Chile ( Site 0206)
Santiago, Region M. de Santiago, Chile
Bradfordhill ( Site 0200)
Santiago, Region M. de Santiago, Chile
The Second Affiliated Hospital of Anhui Medical University ( Site 1179)
Hefei, Anhui, China
Chongqing Cancer Hospital ( Site 1151)
Chongqing, Chongqing Municipality, China
Fujian Province Cancer Hospital ( Site 1178)
Fuzhou, Fujian, China
Sun Yat-Sen University Cancer Center ( Site 1150)
Guangzhou, Guangdong, China
Southern Medical University Nanfang Hospital ( Site 1154)
Guangzhou, Guangdong, China
The Sixth Affiliated Hospital of Sun Yat-sen University ( Site 1159)
Guangzhou, Guangdong, China
Guangxi Medical University Affiliated Tumor Hospital ( Site 1158)
Nanning, Guangxi, China
Hainan General Hospital ( Site 1177)
Haikou, Hainan, China
Showing 40 of 152 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.